Quantcast
Last updated on April 25, 2014 at 5:51 EDT

Latest Antibody Stories

2013-03-04 10:27:22

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells. The study also highlights a potential antibody biomarker that could help predict prognosis and identify which patients are most likely to respond to specific treatments. The research, led by Dr Sophia Karagiannis and...

2013-02-28 16:29:41

LEUVEN, Belgium, February 28, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce today the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children. The Cell publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role...

2013-02-26 16:27:14

Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas. The findings demonstrated preliminary...

2013-02-20 08:28:56

THUNDER BAY, Canada, Feb. 20, 2013 /PRNewswire/ -- IGY Immune Technologies & Life Sciences Inc ("IGY Life Sciences") is pleased to announce the launch of its new sports nutrition supplement brand Vector450 (www.vector450.com) aimed at the athlete market. Vector450 works safely and effectively at the gut level to modulate the immune system and functions to improve its efficiency. According to Terry Dyck, CEO of IGY Life Sciences, "Vector450 is designed to re-balance the immune system,...

2013-02-13 04:20:34

MARTINSRIED and MUNICH, Germany, WELWYN GARDEN CITY, England and BOSTON, February 13, 2013 /PRNewswire/ -- Collaboration Harnesses Heptares' StaRs(R) to Open up New Target Space for Therapeutic Antibodies from MorphoSys' Ylanthia(R) Platform MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody...

Looking For The Key To Immunity
2013-02-04 13:35:50

ESA [ Watch The Video ] Living in space weakens astronauts´ immune systems, researchers have discovered. The findings are providing clues on how to tackle diseases on Earth before symptoms appear. Ever since the first humans ventured into space we have known that astronauts can suffer from common infections that would be quickly dealt with by healthy people on Earth. Until now, it was not clear what was blocking astronauts´ immune systems from working normally. In 2006,...

2013-02-04 10:28:23

Scientists have identified the gene essential for survival of antibody-producing cells, a finding that could lead to better treatments for diseases where these cells are out of control, such as myeloma and chronic immune disorders. The discovery that a gene called Mcl-1 is critical for keeping this vital immune cell population alive was made by researchers at Melbourne's Walter and Eliza Hall Institute. Associate Professor David Tarlinton, Dr Victor Peperzak and Dr Ingela Vikstrom from the...

2013-01-31 08:30:49

SAN FRANCISCO, Jan. 31, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment of Edward C. Albini as chief financial officer. Mr. Albini has more than 25 years of life science industry experience, including more than 14 years in various financial management positions at Genentech. "Ed joins...

2013-01-29 08:30:44

SEATTLE, Jan. 29, 2013 /PRNewswire/ -- LifeSpan BioSciences, Inc. (LSBio), the world's leading provider of high quality, immunohistochemistry (IHC) validated research antibodies, announced today that it has added more than 1,200 proprietary IHC-plus(TM) antibodies to its catalog. The additions include a collection of nearly 900 antibodies targeting G Protein-Coupled Receptors (GPCRs), an important family of proteins that are the targets for nearly one-third of all pharmaceutical drugs...

2013-01-29 08:29:02

Transforming AvidBiologics' pipeline into one of the most competitive in the industry. TORONTO, Jan. 29, 2013 /PRNewswire/ - AvidBiologics Inc., a life sciences company developing antibody-drug conjugates (ADCs), announces the conclusion of an agreement with the National Research Council Canada (NRC) to develop three novel ADCs for the treatment of cancer. The agreement is a partnership under which the three novel, tumor-specific antibodies, which were generated as part of the...